RARE CANCERPancreatic CancerWHO 5th Edition Classification

Pancreatic Neuroendocrine Tumors (pNETs)

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

Tumours of the hormone-producing islet cells of the pancreas. They are entirely distinct from pancreatic adenocarcinoma - typically far slower growing, with a very different treatment pathway and a much better outlook. Functional tumours secrete hormones (insulin, gastrin, glucagon, VIP) and cause characteristic syndromes; the majority are non-functional and present with mass effect.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Do not manage as pancreatic adenocarcinoma - the pathway and prognosis differ entirely
Who It Affects

Adults, median 50-60; earlier in hereditary syndromes such as MEN1 and VHL

Annual Incidence

Approximately 4-5 per million per year and rising with incidental detection

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Non-functional: abdominal pain, jaundice, or an incidental finding on imaging
Insulinoma: confusion, sweating and collapse relieved by eating
Gastrinoma: severe recurrent peptic ulcers and diarrhoea (Zollinger-Ellison syndrome)
Glucagonoma: a migrating rash, new diabetes and weight loss
VIPoma: profuse watery diarrhoea with low potassium

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

MEN1DAXX/ATRXmTOR pathway (TSC2, PTEN)Ki-67 index for gradingSomatostatin receptor expression on Ga-68 DOTATATE PET

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Surgical resection or enucleation, curative for localised disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Somatostatin analogues (octreotide, lanreotide) for control of growth and hormone symptoms

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Peptide receptor radionuclide therapy with lutetium-177 dotatate for somatostatin-receptor-positive disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Everolimus or sunitinib as targeted systemic options

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Capecitabine-temozolomide chemotherapy, particularly effective in pNETs

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

6

Liver-directed therapy - embolisation or ablation - for liver-dominant metastases

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

7

Genetic testing for MEN1, VHL, NF1 and tuberous sclerosis where indicated

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Considerably better than pancreatic adenocarcinoma and highly dependent on grade. Well-differentiated G1/G2 tumours have five-year survival above 80-90% when localised, and multi-year survival is common even with liver metastases. Poorly differentiated neuroendocrine carcinoma is a separate, far more aggressive disease.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Sequencing and combining PRRT with other systemic agents, next-generation somatostatin-receptor radioligands, and immunotherapy in high-grade disease are the main research fronts.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Pancreatic Neuroendocrine Tumors

Browse All Oncologists

Dr. James Yao

Medical Oncologist

20+ yrs exp

MD Anderson

Houston, USA

Medical OncologyNeuroendocrine TumorsEverolimus/Sunitinib
Vetted DirectoryConsult Specialist

Dr. Thng Choon Hua

Endocrinologist

15+ yrs exp

SGH

Singapore, Singapore

EndocrinologypNETsSSA Therapy/PRRT
Vetted DirectoryConsult Specialist

Prof. Kjell Öberg

Endocrine Oncologist

40+ yrs exp

Uppsala University

Uppsala, Sweden

Endocrine OncologyNETsENETS Guidelines
Vetted DirectoryConsult Specialist

Dr. C. S. Pramesh

GI Surgical Oncologist, Director

25+ yrs exp

Tata Memorial

Mumbai, India

GI Surgical OncologyPancreas SurgerypNETs
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

Independent Tumor Board Review

Facing a Diagnosis of Pancreatic Neuroendocrine Tumors?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult